Using Artificial Intelligence to Analyze FSHD Data The FSHD Society announced that it is launching a collaboration involving the FSHD Clinical Trial Research Network (CTRN) and BullFrogAI, an innovator in… Read More »
Applying AI to FSHD research
AMRA Medical cites FSHD Society’s support of its MRI study
Hats off to AMRA Medical and Avidity Biosciences for adding magnetic resonance imaging (MRI) to the landmark MOVE study. The FSHD Society helped to build and expand the clinical trial… Read More »
Record Year in Grant Funding
$2 million allocated for 15 projects by Jamshid Arjomand, PhD, FSHD Society Following a lull imposed by the global pandemic, the FSHD Society’s support for research grants has come back… Read More »
ReDUX4 trial result exceeds expectations
By June Kinoshita, Director of Research and Patient Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”—Fulcrum Therapeutics Fulcrum Therapeutics announced today that… Read More »
Hot off the press – FSHD Advocate
Our new issue of the FSHD Advocate, the first of 2021, is now available online. For those of you who receive our flagship magazine by the postal service, it will… Read More »